Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

Hypertension

Volumn 32, Issue 6, 1998, Pages 965-971

  Brown, Nancy J ^a,b   Agirbasli, Mehmet A ^a   Williams, Gordon H ^c   Litchfield, W Reid ^c   Vaughan, Douglas E ^a,b  

^a Depts of Medicine and Pharmacology   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II; Fibrinolysis; Plasminogen activator inhibitor 1; Quinapril; Renin; Sodium; Tissue plasminogen activator

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; QUINAPRIL; RENIN; SODIUM; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CIRCADIAN RHYTHM; ENZYME INHIBITION; FIBRINOLYSIS; HEART INFARCTION; HEMODYNAMICS; HORMONE RESPONSE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SODIUM DEPLETION; SODIUM EXCRETION; THROMBOSIS;

EID: 0032407095     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.6.965     Document Type: Article

References (44)

1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324: 1098-1104.
3. Hypertension Detection and Follow-up Program Cooperative Research Group. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. Circulation. 1984;70:996-1003.
4. Multiple Risk Factor Intervention Trial Research Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1985;55:1-15.
5. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
6. Hayek T, Keidar S, Mei-Yi, Oiknine J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis progression in apo E deficient mice. Circulation. 1995;92(suppl I):I-625. Abstract.
7. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992; 327:669-677.
8. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
9. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest. 1995;95:995-1001.
10. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation. 1993;87:1969-1973.
11. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987; 69:381-387.
12. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
13. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78:656-660.
14. Hamsten A, de Fairde U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
15. Erdos EG. The angiotensin I converting enzyme. Fed Proc. 1977;36: 1760-1765.
16. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of ACE inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 1996;279:703-712.
17. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522-525.
18. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835-839.
19. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions. 1992;38:285-291.
20. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast acting inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemost. 1984;51:392-395.
21. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue plasminogen activator and plasminogen activator inhibitor. Circulation. 1992;85:1822-1827.
22. Workman RJ, Sussman CR, Burkitt DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med. 1979;93:847-856.
23. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B. 1994;653:131-138.
24. Tuck ML, Williams GH, Cain JP, Sullivan JM, Dluhy RG. Relation of age, diastolic blood pressure, and known duration of hypertension to the presence of low-renin essential hypertension. Am J Cardiol. 1973;32: 637-642.
25. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
26. Pederson OD, Gram J, Bagger H, Keller N, Jespersen J. Regulation of tissue-type plasminogen activator mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischemic heart disease: possible unfavourable effects of diuretics. Coron Artery Dis. 1994;5:617-623.
27. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor. Circulation. 1989;79:101-106.
28. Chandler WL, Mornin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res. 1990; 58:1-12.
29. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315-1322.
30. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation. 1990;82:897-902.
31. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation. 1995;91:1341-1346.
32. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: JH Laragh, BM Brenner, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990: 1287-1317.
33. Hollenberg NK, Chenitz WR, Adams DF, Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotenstn II in normal man. J Clin Invest. 1974;54:34-42.
34. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res. 1974;40:69.-77.
35. Heaton JH, Kathju S, Gelehrter TD. Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. Mol Endocrinol. 1992;6:53-60.
36. Heaton JH, Gelehrter TD. Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. Mol Endocrinol. 1989;3:349-355.
37. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA. 1988;85:5525-5529.
38. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl):S65-S72.
39. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 1996;93:1073-1078.
40. Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA, on behalf of the HEART Study Investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation. 1997;96:442-447.
41. Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Celentano E, Panico S, Diminno G. Plasminogen activator inhibitor 1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol. 1997;17: 2082-2087.
42. Kim D-K, Kim J-W, Kim S, Gwon H-C, Ryu J-C, Huh J-E, Choo J-A, Choi Y, Rhee C-H, Lee W-R. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitors-1. Arterioscler Thromb Vasc Biol. 1997;17: 3242-3247.
43. Wright RA, Flapan AD, Alberti KG, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24: 67-73.
44. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response. J Cardiovasc Pharmacol. 1980;2:339-346.